Mangoceuticals Inc

Mangoceuticals Inc (MGRX) Stock Analysis

$0.200

+0.009 (+4.28%)At close

Loading chart…
High
0.209
Open
0.192
VWAP
0.20
Volume
319.40K
Mkt Cap
9.35M
Low
0.186
Amount
63.39K
EV/EBITDA, TTM
0.00

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.

AI analysis of Mangoceuticals Inc (MGRX)

Sell

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

Valuation Metrics

The current forward P/E ratio for Mangoceuticals Inc (MGRX) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for MGRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MGRX

$1.71

Scenario price

B

Base

Base · 50%MGRX

$1.48

Scenario price

B

Bear

Bear · 25%MGRX

$1.39

Scenario price

Events Timeline

2026-10-01 (ET)

16:00:00

Mangoceuticals' Former Subsidiary Secures $2.5M Investment

2026-07-30 (ET)

09:30:00

Mangoceuticals Enters Business Combination Agreement with Nuclea Energy

2026-03-17 (ET)

16:20:00

Mangoceuticals Sues Clarity Ventures for Over $73M

2026-01-13 (ET)

17:40:00

Mangoceuticals Files to Sell 2.64M Shares of Common Stock

2025-12-19 (ET)

07:40:00

Mangoceuticals Partners with Cube Group for Up to $100M Solana Digital Asset Strategy

News

MGRX FAQ — answered by Alphio AI

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading